Recent News

• 10.03.2025 - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
• 10.03.2025 - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
• 09.26.2025 - Charles Carter

Recent Filings

• 10.03.2025 - EX-99.1 EX-99.1
• 10.03.2025 - 8-K Current report
• 09.16.2025 - 8-K Current report
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.10.2025 - 8-K Current report
• 07.09.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors